These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7742747)

  • 21. Stabilization of juvenile metachromatic leukodystrophy after bone marrow transplantation: a 13-year follow-up.
    Görg M; Wilck W; Granitzny B; Suerken A; Lukacs Z; Ding X; Schulte-Markwort M; Kohlschütter A
    J Child Neurol; 2007 Sep; 22(9):1139-42. PubMed ID: 17890417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Donor/recipient mixed chimerism does not predict graft failure in children with beta-thalassemia given an allogeneic cord blood transplant from an HLA-identical sibling.
    Lisini D; Zecca M; Giorgiani G; Montagna D; Cristantielli R; Labirio M; Grignani P; Previderè C; Di Cesare-Merlone A; Amendola G; Bergami E; Mastronuzzi A; Maccario R; Locatelli F
    Haematologica; 2008 Dec; 93(12):1859-67. PubMed ID: 18945748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of recombinant human granulocyte colony-stimulating factor in children given allogeneic bone marrow transplantation for acute or chronic leukemia.
    Locatelli F; Pession A; Zecca M; Bonetti F; Prete L; Carrà AM; Prete A; Montagna D; Comoli P; Taibi RM; Paolucci G
    Bone Marrow Transplant; 1996 Jan; 17(1):31-7. PubMed ID: 8673051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. White matter dysfunction and its neuropsychological correlates: a longitudinal study of a case of metachromatic leukodystrophy treated with bone marrow transplant.
    Shapiro EG; Lipton ME; Krivit W
    J Clin Exp Neuropsychol; 1992 Jul; 14(4):610-24. PubMed ID: 1356997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unrelated donor bone marrow transplantation in Fanconi anaemia: the Leiden experience.
    Zwaan CM; Van Weel-Sipman MH; Fibbe WE; Oudshoorn M; Vossen JM
    Bone Marrow Transplant; 1998 Mar; 21(5):447-53. PubMed ID: 9535036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hematopoietic progenitor cells from allogeneic bone marrow transplant donors circulate in the very early post-transplant period.
    Katayama Y; Mahmut N; Takimoto H; Maeda Y; Yano T; Kojima K; Azuma T; Hara M; Imajyo K; Takahashi S; Kai T; Ohno Y; Miyamoto T; Nagafuji K; Matsue K; Takenaka K; Teshima T; Shinagawa K; Ishimaru F; Omoto E; Harada M
    Bone Marrow Transplant; 1999 Apr; 23(7):659-65. PubMed ID: 10218841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia.
    Byrne JL; Stainer C; Cull G; Haynes AP; Bessell EM; Hale G; Waldmann H; Russell NH
    Bone Marrow Transplant; 2000 Feb; 25(4):411-7. PubMed ID: 10723585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Second allogeneic bone marrow transplants from unrelated donors for graft failure following initial unrelated donor bone marrow transplantation.
    Grandage VL; Cornish JM; Pamphilon DH; Potter MN; Steward CG; Oakhill A; Marks DI
    Bone Marrow Transplant; 1998 Apr; 21(7):687-90. PubMed ID: 9578308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
    Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
    Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Matched unrelated donor marrow transplantation in patients with advanced acute leukemia.
    Greinix HT; Reiter E; Schulenburg A; Keil F; Lechner K; Fischer G; Rosenmayr A; Leitner G; Kalhs P
    Bone Marrow Transplant; 1998 Dec; 22 Suppl 4():S53-6. PubMed ID: 9916636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
    Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Ball E; Cook D; Andresen S; Kuczkowski E; Bolwell B
    Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complete donor T cell chimerism is accomplished in patients transplanted with bone marrow grafts containing a fixed low number of T cells.
    Verdonck LF; van Blokland WT; Bosboom-Kalsbeek EK; van Heugten HG; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1996 Aug; 18(2):389-95. PubMed ID: 8864451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors.
    Martin P; Bleyzac N; Souillet G; Galambrun C; Bertrand Y; Maire PH; Jelliffe RW; Aulagner G
    Bone Marrow Transplant; 2003 Nov; 32(9):881-7. PubMed ID: 14561988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
    Weisdorf D; Filipovich A; McGlave P; Ramsay N; Kersey J; Miller W; Blazar B
    Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of 500 bone marrow transplants from unrelated donors (UR-BMT) facilitated by the Japan Marrow Donor Program: confirmation of UR-BMT as a standard therapy for patients with leukemia and aplastic anemia.
    Kodera Y; Morishima Y; Kato S; Akiyama Y; Sao H; Matsuyama T; Kawa K; Sakamaki H; Nakagawa S; Hirabayashi N; Dohi H; Okamoto S; Hiraoka A; Gondo H; Tsuchida M; O H; Harada M; Asano S; Juji T; Sasazuki T; Takaku F
    Bone Marrow Transplant; 1999 Nov; 24(9):995-1003. PubMed ID: 10556959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary human keratinocytes as targets in predicting acute graft-versus-host disease following HLA-identical bone marrow transplantation.
    van Dijk AM; Kessler FL; Verdonck LF; Stadhouders-Keet SA; van Lier RA; de Gast GC; Otten HG
    Br J Haematol; 2000 Dec; 111(3):791-6. PubMed ID: 11122139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Preliminary study of HLA haplotype matched and T-cell undepleted allogeneic bone marrow transplantation for treatment of leukemia].
    Ji S; Chen H; Wang H
    Zhonghua Xue Ye Xue Za Zhi; 2001 Aug; 22(8):408-10. PubMed ID: 11718090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced-intensity bone marrow transplantation from an alternative unrelated donor for myelodysplastic syndrome of first-donor origin.
    Komeno Y; Kanda Y; Kandabashi K; Kawazu M; Goyama S; Takeshita M; Nannya Y; Niino M; Nakamoto T; Kurokawa M; Tsujino S; Ogawa S; Aoki K; Chiba S; Motokura T; Hirai H
    Am J Hematol; 2003 Mar; 72(3):220-2. PubMed ID: 12605397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unrelated donor marrow transplantation for inborn errors.
    Miano M; Porta F; Locatelli F; Miniero R; La Nasa G; Di Bartolomeo P; Giardini C; Messina C; Balduzzi A; Testi AM; Garbarino L; Lanino E; Crescenzi F; Zecca M; Dini G
    Bone Marrow Transplant; 1998 Apr; 21 Suppl 2():S37-41. PubMed ID: 9630323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.